258 related articles for article (PubMed ID: 7994271)
41. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
Wadehra N; Farag S; Bolwell B; Elder P; Penza S; Kalaycio M; Avalos B; Pohlman B; Marcucci G; Sobecks R; Lin T; Andrèsen S; Copelan E
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1343-9. PubMed ID: 17162217
[TBL] [Abstract][Full Text] [Related]
42. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.
Anderson JE; Appelbaum FR; Schoch G; Gooley T; Anasetti C; Bensinger WI; Bryant E; Buckner CD; Chauncey T; Clift RA
J Clin Oncol; 1996 Jan; 14(1):220-6. PubMed ID: 8558201
[TBL] [Abstract][Full Text] [Related]
43. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
Wall DA; Carter SL; Kernan NA; Kapoor N; Kamani NR; Brochstein JA; Frangoul H; Goyal RK; Horan JT; Pietryga D; Wagner JE; Kurtzberg J;
Biol Blood Marrow Transplant; 2005 Aug; 11(8):637-46. PubMed ID: 16041314
[TBL] [Abstract][Full Text] [Related]
44. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
Spitzer TR; Cottler-Fox M; Torrisi J; Cahill R; Greenspan A; Lynch M; Deeg HJ
Bone Marrow Transplant; 1989 Sep; 4(5):559-65. PubMed ID: 2676044
[TBL] [Abstract][Full Text] [Related]
45. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications.
Beelen DW; Trenschel R; Casper J; Freund M; Hilger RA; Scheulen ME; Basara N; Fauser AA; Hertenstein B; Mylius HA; Baumgart J; Pichlmeier U; Hahn JR; Holler E
Bone Marrow Transplant; 2005 Feb; 35(3):233-41. PubMed ID: 15592494
[TBL] [Abstract][Full Text] [Related]
46. Allogeneic bone marrow transplantation for hematological malignancies following therapy with high doses of busulphan and cyclophosphamide.
Angelucci E; Polchi P; Lucarelli G; Galimberti M; Baronciani D; Giardini C; Durazzi SM; Moretti L; Donati M
Haematologica; 1989; 74(5):455-61. PubMed ID: 2511115
[TBL] [Abstract][Full Text] [Related]
47. A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies.
Vey N; De Prijck B; Faucher C; Stoppa AM; Sainty D; Lafage M; Bouabdallah R; Chabannon C; Camerlo J; Gastaut JA; Maraninchi D; Blaise D
Bone Marrow Transplant; 1996 Sep; 18(3):495-9. PubMed ID: 8879608
[TBL] [Abstract][Full Text] [Related]
48. Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies.
deMagalhaes-Silverman M; Bloom EJ; Donnenberg A; Lister J; Pincus S; Rybka WB; Ball ED
Bone Marrow Transplant; 1996 Mar; 17(3):329-33. PubMed ID: 8704682
[TBL] [Abstract][Full Text] [Related]
49. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
[TBL] [Abstract][Full Text] [Related]
50. Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia.
Copelan EA; Penza SL; Elder PJ; Belt PS; Scholl MD; Hehmeyer DM; Ezzone SA; Bechtel TP; Avalos BR
Bone Marrow Transplant; 1996 Nov; 18(5):907-11. PubMed ID: 8932844
[TBL] [Abstract][Full Text] [Related]
51. The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia.
Rosales F; Naparstek E; Varadi G; Or R; Slavin S; Nagler A
Leuk Res; 1999 Oct; 23(10):947-52. PubMed ID: 10573141
[TBL] [Abstract][Full Text] [Related]
52. Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
Blume KG; Long GD; Negrin RS; Chao NJ; Kusnierz-Glaz C; Amylon MD
Bone Marrow Transplant; 1994; 14 Suppl 4():S9-10. PubMed ID: 7728133
[TBL] [Abstract][Full Text] [Related]
53. Big BU/CY is associated with a favorable long-term outcome in patients allotransplanted for chronic myelogenous leukemia in chronic phase.
Bonini A; Bandini G; Rosti G; Rondelli D; Testoni N; Remiddi C; Motta MR; Rizzi S; Mangianti S; Campanini E; Zuffa E; Tura S
Bone Marrow Transplant; 1998 Jun; 21(11):1085-9. PubMed ID: 9645569
[TBL] [Abstract][Full Text] [Related]
54. Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma.
de Magalhaes-Silverman M; Lister J; Rybka W; Wilson J; Ball E
Bone Marrow Transplant; 1997 Apr; 19(8):777-81. PubMed ID: 9134168
[TBL] [Abstract][Full Text] [Related]
55. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies.
Bandini G; Belardinelli A; Rosti G; Calori E; Motta MR; Rizzi S; Benini C; Tura S
Bone Marrow Transplant; 1994 May; 13(5):577-81. PubMed ID: 8054910
[TBL] [Abstract][Full Text] [Related]
56. Allogeneic bone marrow transplantation following busulfan and 90 mg/kg of cyclophosphamide.
Avalos BR; Klein JL; Kapoor N; Copelan EA
Bone Marrow Transplant; 1993 Dec; 12(6):655-8. PubMed ID: 8136749
[TBL] [Abstract][Full Text] [Related]
57. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
[TBL] [Abstract][Full Text] [Related]
58. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
Galimberti M; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Giardini C; Gaziev D; Erer B; Ripalti M; Rapa S
Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089
[TBL] [Abstract][Full Text] [Related]
59. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
[TBL] [Abstract][Full Text] [Related]
60. A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation.
Ritchie DS; Szer J; Roberts AW; Shuttleworth P; Grigg AP
Bone Marrow Transplant; 2002 Nov; 30(10):645-50. PubMed ID: 12420202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
